A Phase 3, Randomized, Open-label, Parallel-arm, Active-controlled, Multicenter Study to Evaluate Safety and Efficacy of ALXN1850 Versus Asfotase Alfa Administered Subcutaneously in Pediatric (2 to < 12 years of age) Participants with Hypophosphatasia (HPP) Previously Treated with Asfotase Alfa

Status: Recruiting

Eligibility Criteria

Sex: Male or Female
Age Group: Up to 18 years old
This study is NOT accepting healthy volunteers

Inclusion Criteria:

- 2 to 11 years old - diagnosis of Hypophosphatasia (HPP) - treated with 6 mg/kg/ week of asfotase alfa via subcutaneous injection administered as either 2mg/kg 3 times per week or 1 mg/kg 6 times per week for at least 6 months

Exclusion Criteria:

- primary or secondary hyperparathyroidism - hypoparathyroidism, unless secondary to HPP - any new fracture within past 12 weeks - body weight less than 10 kg (22 pounds)

Conditions & Interventions

Conditions:
Children's Health, Rare Diseases
Keywords:
HPP, Hypophosphatasia

More Information

Description: This is a study to evaluate the safety and efficacy of ALXN1850 in pediatric participants with hypophosphatasia who have been treated with asfotase alfa for at least 6 months.
Study Contact: Kyriakie Sarafoglou - saraf010@umn.edu
Principal Investigator: Kyriakie Sarafoglou
IRB Number: STUDY00020817